Kevin J. Bitterman is a Principal at Polaris Venture Partners. Kevin joined Polaris in 2004 and focuses on investments in the life sciences.

Experience:
Prior to joining Polaris, Kevin completed his Ph.D. in genetics at Harvard Medical School.  His doctoral research focused on the molecular regulation of caloric restriction and on modulation of a novel class of protein deacetylases.  Kevin has authored papers in several top tier journals, is an inventor on multiple patents and is a cofounder of Genocea Biosciences and Sirtris Pharmaceuticals (GSK).

Boards:
Kevin currently represents Polaris as a Director of Biolex Therapeutics, EPacing Inc., Follica Inc., Genocea Biosciences, Kala Pharmaceuticals, Parasol Therapeutics, and Taris Biomedical.  Additionally, Kevin is a Board Observer to Pulmatrix Inc.

Education:
Prior to obtaining his Ph.D. at Harvard Medical School, Kevin earned a B.A. with Highest Honors from Rutgers College with a major in Biological Sciences and a minor in Philosophy.